Darzalex performs well in Janssen's rare disease study
New data from Janssen supports the use of Genmab-developed drug Darzalex Faspro to treat the rare disease AL amyloidosis.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
On Wednesday, Johnson & Johnson-company Janssen Pharmaceuticals, which produces and sells Genmab's blockbuster drug Darzalex, announced positive trial results for the subcutaneous (under the skin) version of this drug for treating the rare disease amyloid light-chain (AL) amyloidosis.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
